Gyre Therapeutics (GYRE) announced Han Ying has stepped down as CEO and will transition into the role of senior VP, science and will oversee research and discovery activities to support Gyre’s fibrosis focused pipeline. Ping Zhang, executive chairman, has been appointed interim CEO, and will lead the company’s day-to-day operations and strategic global expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE: